

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/720,954	11/24/2003	Vladimir Grushin	PE0649USDIV8	5280
23906	7590 09/28/2005		EXAMINER	
E I DU PONT DE NEMOURS AND COMPANY			RODGERS, COLLEEN E	
220.121.11	'ENT RECORDS CENTE ILL PLAZA 25/1128	ER	ART UNIT	PAPER NUMBER
4417 LANCA	ASTER PIKE		2813	
WILMINGTO	ON, DE 19805		DATE MAILED: 09/28/200	5

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	\sim
	10/720,954	GRUSHIN ET AL.	(m)
Office Action Summary	Examiner	Art Unit	
	Colleen E. Rodgers	2813	
The MAILING DATE of this communicati Period for Reply	ion appears on the cover sheet wit	h the correspondence addre	ss -
A SHORTENED STATUTORY PERIOD FOR THE MAILING DATE OF THIS COMMUNICATORY Extensions of time may be available under the provisions of 37 after SIX (6) MONTHS from the mailing date of this communicator of the period for reply specified above is less than thirty (30) dayone if NO period for reply is specified above, the maximum statutor Failure to reply within the set or extended period for reply will, any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	TION. CFR 1.136(a). In no event, however, may a restion. ys, a reply within the statutory minimum of thirty y period will apply and will expire SIX (6) MONT by statute, cause the application to become ABA	ply be timely filed (30) days will be considered timely. HS from the mailing date of this comm	unication.
Status			
1) Responsive to communication(s) filed or	n <i>21 June <u>2005</u>.</i>	•	
,	☑ This action is non-final.		
3) Since this application is in condition for a closed in accordance with the practice u	·		erits is
Disposition of Claims			
4) ☐ Claim(s) 19 is/are pending in the application 4a) Of the above claim(s) is/are with 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 19 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction	rithdrawn from consideration.		
Application Papers			
9) The specification is objected to by the Ex		·	
10) The drawing(s) filed on is/are: a)		•	
Applicant may not request that any objection	-		4 404/4\
Replacement drawing sheet(s) including the 11) The oath or declaration is objected to by	•	·	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for to a) All b) Some * c) None of: 1. Certified copies of the priority doc 2. Certified copies of the priority doc 3. Copies of the certified copies of the application from the International * See the attached detailed Office action for	euments have been received. Euments have been received in Ap ne priority documents have been in Bureau (PCT Rule 17.2(a)).	oplication No received in this National Sta	age
Attachment(s)			
1) X Notice of References Cited (PTO-892)		ummary (PTO-413)	
2) Notice of Draftsperson's Patent Drawing Review (PTO- 3) Information Disclosure Statement(s) (PTO-1449 or PTO Paper No(s)/Mail Date 05\18\05)/Mail Date formal Patent Application (PTO-15 	52)
Detect and Traction 1 Office			

Art Unit: 2813

DETAILED ACTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 21 June 2005 has been entered.

Claim Rejections - 35 USC § 103

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
 - 1. Determining the scope and contents of the prior art.
 - 2. Ascertaining the differences between the prior art and the claims at issue.
 - 3. Resolving the level of ordinary skill in the pertinent art.
 - 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Art Unit: 2813

4. Claim 19 is rejected under 35 U.S.C. 103(a) as being unpatentable over the article **Dedeian** et al. "A new synthetic route to the preparation of a series of strong photoreducing agents: fac trisortho-metalated complexes of iridium(III) with substituted 2 phenylpyridines," *Inorganic Chemistry* 1999, 30, p. 1685-1687, in view of **Baldo** et al (WO 00/70655).

Dedeian et al discloses substituted phenylpyridine ligands for Ir(III), as shown in Figure 1 on page 1686. Table 1, on the same page, shows the groups with which the phenylpyridine may be substituted. None of adjacent pairs R₁-R₄ and R₅-R₉ are joined. The F, F₃C and MeO functional groups read on the presently claimed compounds. While Dedeian et al discloses phenylpyridine ligands rather than the compound of the instant case, it is admitted in applicants' specification that the phenylpyridine and phenylpyrimidine compounds claimed are used to make compounds of the type disclosed in Dedeian et al.

"In another embodiment, the present invention is directed to substituted 2-phenylpyridine, phenylpyrimidine, and phenylquinoline precursor compounds from which the above Ir(III) compounds are made." (Specification page 2, lines 29-31, emphasis added.)

Dedeian et al does not locate the substituent groups F, CF₃ and MeO on the phenylpyridine ligands that match those selected locations from the table in the instant case as claimed in claim 19.

Baldo et al, like Dedeian et al, discloses substituted phenylpyridine ligands for Ir(III), and teaches that the substituent groups can be located in any position on either ring of the phenylpyridine ligand. Baldo et al indicates that moving the functional group beneficially "give[s] different color emission," "different carrier transport" and "alter[s] the emissive properties" (see p. 14-15).

It would have been obvious for one of ordinary skill in the art at the time of invention to locate the substituents of **Dedeian** et al at each specific location on the phenylpyridine ring to

· Art Unit: 2813

beneficially effect the emissive properties of the Ir(III) complex, as taught to be beneficial in **Baldo** et al.

5. Claim 19 is rejected under 35 U.S.C. 103(a) as being unpatentable over the article **Djurovich** et al. "Ir(III) cyclometalated complexes as efficient phosphorescent emitters in polymer blend and organic LEDs," *Polymer Preprints* 2000, 41(1), p. 770-771, in view of **Baldo** et al (WO 00/70655).

Djurovich et al discloses the compound *fac* tris-2-(4'-5'-difluorophenyl)pyridine Ir(III) complex, as shown in Figure 1, structure 1. While **Djurovich** et al discloses phenylpyridine complexes rather than the precursor compound of the instant case, it is admitted in applicants' specification that the phenylpyridine and phenylpyrimidine compounds claimed are used to make complexes of the type disclosed in **Djurovich** et al.

"In another embodiment, the present invention is directed to substituted 2-phenylpyridine, phenylpyrimidine, and phenylquinoline precursor compounds from which the above Ir(III) compounds are made." (Specification page 2, lines 29-31, emphasis added.)

Djurovich et al does not locate the substituent groups F and CF₃ on the phenylpyridine ligands that match those selected locations from the table in the instant case as claimed in claim 19.

Baldo et al, like Dedeian et al, discloses substituted phenylpyridine ligands for Ir(III), and teaches that the substituent groups can be located in any position on either ring of the phenylpyridine ligand. Baldo et al indicates that moving the functional group beneficially "give[s] different color emission," "different carrier transport" and "alter[s] the emissive properties" (see p. 14-15).

It would have been obvious for one of ordinary skill in the art at the time of invention to locate the substituents of **Dedeian** et al at each specific location on the phenylpyridine ring to

Art Unit: 2813

beneficially effect the emissive properties of the Ir(III) complex, as taught to be beneficial in **Baldo** et al.

Response to Arguments

- 6. Applicant's arguments with respect to compound 2-c have been considered but are moot in view of the cancellation thereof.
- 7. Applicant's arguments, see Remarks, filed 21 June 2005, with respect to the rejection(s) of compound 2-g under 35 USC § 102(b) have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of 35 U.S.C. § 103(a) as explained above.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Colleen E. Rodgers whose telephone number is (571) 272-0237. The examiner can normally be reached on Monday through Friday, 7:30 AM to 4:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Carl Whitehead can be reached on (571) 272-1702. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 2813

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

CER

GEORGE ECKERT
PRIMARY FXAMINER